iiinova — where your digital self keeps evolving

Precision Oncology News @preconcnews.bsky.social · 19/02/2026

A study evaluated agreement between 10 AI digital pathology tools in assessing IHC-based HER2 expression and found the most variability in identifying HER2-low samples.

precisionmedicineonline.com

AI Tools Stumped By HER2-Low Breast Cancer Just Like Pathologists, Study Finds

000

Precision Oncology News @preconcnews.bsky.social · 19/02/2026

The gene therapy, which was acquired by Novartis in 2023, is also being tested in a separate Phase I/II trial of pediatric patients.

precisionmedicineonline.com

UCSD Scientists Report Early Success With Cystinosis Gene Therapy in First-in-Human Trial

000

Precision Oncology News @preconcnews.bsky.social · 18/02/2026

Distance, lack of coverage, and mistrust have limited Indigenous patients' access to basic and advanced medicine, but cancer centers are embracing strategies to change that.

precisionmedicineonline.com

When Even Basic Care Is Lacking in Indigenous Communities, What Does Precision Medicine Look Like?

000

Precision Oncology News @preconcnews.bsky.social · 18/02/2026

Federal immigration enforcement action may be winding down, but healthcare professionals say the "collective trauma" ICE inflicted on the community will be long lasting.

precisionmedicineonline.com

Minneapolis Genetics Professionals Speak Out on Public Health Harms of ICE Crackdown

000

Precision Oncology News @preconcnews.bsky.social · 17/02/2026

Distance, lack of coverage, and mistrust have limited Indigenous patients' access to basic and advanced medicine, but cancer centers are embracing strategies to change that.

precisionmedicineonline.com

When Even Basic Care Is Lacking in Indigenous Communities, What Does Precision Medicine Look Like?

000

Precision Oncology News @preconcnews.bsky.social · 13/02/2026

The company is expecting additional readouts this year from studies of cancer vaccine intismeran autogene, which is being tested in late-stage trials.

precisionmedicineonline.com

Amid Flu Vaccine Turmoil, Moderna Expects Strong Oncology Data in 2026

000

Precision Oncology News @preconcnews.bsky.social · 13/02/2026

Vertex posted revenue and earnings for Q4 and full-year 2025 that hovered around consensus Wall Street estimates, but CRISPR Therapeutics missed expectations.

precisionmedicineonline.com

Vertex, CRISPR Therapeutics Record $115.8M in 2025 Casgevy Sales

000

Precision Oncology News @preconcnews.bsky.social · 12/02/2026

The firm is developing RNAi drugs to treat neurological diseases by silencing genes in the brain, the first of which it will nominate this year.

precisionmedicineonline.com

With $39M in Series A Funding, Irish Biotech Aerska Aims to Deliver RNAi Drugs to the Brain

000

Precision Oncology News @preconcnews.bsky.social · 12/02/2026

The firm will test the FSHR-targeting lira-cel at up to 100-tmes higher doses after seeing better than expected outcomes at lower doses in a Phase I trial.

precisionmedicineonline.com

Anixa Testing Ovarian Cancer CAR-T Therapy at Higher Doses

000

Precision Oncology News @preconcnews.bsky.social · 11/02/2026

The company is continuing to prepare for a second half rollout of anito-cel if it is approved by the FDA.

precisionmedicineonline.com

Gilead's Cell Therapy Sales Tumble for Third Quarter in a Row

000

Precision Oncology News @preconcnews.bsky.social · 10/02/2026

Tagrisso, Imfinzi, Truqap, and Enhertu all reported double-digit sales growth during the fourth quarter and full-year 2025 versus the same periods in 2024.

precisionmedicineonline.com

AstraZeneca Records 22 Percent Growth in Q4 Oncology Business as Precision Drug Sales Surge

000

Precision Oncology News @preconcnews.bsky.social · 10/02/2026

The firm will test the FSHR-targeting lira-cel at up to 100-tmes higher doses after seeing better than expected outcomes at lower doses in a Phase I trial.

precisionmedicineonline.com

Anixa Testing Ovarian Cancer CAR-T Therapy at Higher Doses

000

Precision Oncology News @preconcnews.bsky.social · 06/02/2026

Biogen's "growth products" — about a half-dozen products including Leqembi — contributed $800 million to the firm's $2.28 billion in Q4 2025 revenue.

precisionmedicineonline.com

Biogen Holds on to Leqembi Lead in Overall Anti-Amyloid Market, Bolstered by Maintenance Indication

000

Precision Oncology News @preconcnews.bsky.social · 06/02/2026

Dementia care isn't just about new drugs, said the author of a cost-effectiveness study comparing collaborative care, Leqembi, or combining both.

precisionmedicineonline.com

Alzheimer's Patients May Benefit From New Drugs, Collaborative Program Integration, UCSF Finds

000

Precision Oncology News @preconcnews.bsky.social · 05/02/2026

Dementia care isn't just about new drugs, said the author of a cost-effectiveness study comparing collaborative care, Leqembi, or combining both.

precisionmedicineonline.com

Alzheimer's Patients May Benefit From New Drugs, Collaborative Program Integration, UCSF Finds

000

Precision Oncology News @preconcnews.bsky.social · 04/02/2026

The firm provided updates alongside Q4 and full-year 2025 financial results, and reported $19.29 billion and $65.18 billion in revenue, respectively.

precisionmedicineonline.com

Eli Lilly Drops Frontotemporal Dementia Gene Therapy; Touts Kisunla as Anti-Amyloid Leader

000

Precision Oncology News @preconcnews.bsky.social · 04/02/2026

The company is advancing TG4050 in head and neck cancer and possibly to other tumor types based on encouraging Phase I data.

precisionmedicineonline.com

Transgene Moving Personalized Vaccine to Phase II, Eyeing Trial Sites in US, Canada

000

Precision Oncology News @preconcnews.bsky.social · 04/02/2026

Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology portfolio increased 9 percent year over year.

precisionmedicineonline.com

Pfizer Reports 9 Percent Increase in Q4 Oncology Revenue as Ibrance Patent Cliff Looms

000

Precision Oncology News @preconcnews.bsky.social · 03/02/2026

The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a deadline it hopes to hold off a bit longer.

precisionmedicineonline.com

Merck Pushes Back on Slowdown Assumptions, Defends Oncology Pipeline Potential

000

Precision Oncology News @preconcnews.bsky.social · 03/02/2026

CIRM will fund validation awards to bring therapies to human trials and innovation awards to those that "push the boundaries" of platform approaches.

precisionmedicineonline.com

CIRM Earmarks $100M For Rare Disease Platform Therapies in New RAPID Program

000

Precision Oncology News @preconcnews.bsky.social · 03/02/2026

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat genetic hearing loss.

precisionmedicineonline.com

Eli Lilly Expanding Hearing Loss Gene Therapy Push With $1B Seamless Therapeutics Pact

000

Precision Oncology News @preconcnews.bsky.social · 02/02/2026

Three blood cancer organizations have appealed a NICE draft guidance, which could make the therapy unavailable for mantle cell lymphoma patients.

precisionmedicineonline.com

Advocacy Groups Challenge NICE Decision to Limit Tecartus Access in England, Wales

000

Precision Oncology News @preconcnews.bsky.social · 01/02/2026

The nonprofit biotech recently licensed the gene therapy from Boston Children's Hospital and plans to bring it to low- and middle-income countries.

precisionmedicineonline.com

Caring Cross Plans Sickle Cell Gene Therapy Trials in India, Brazil While Amassing Data for FDA

010

Precision Oncology News @preconcnews.bsky.social · 31/01/2026

The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.

precisionmedicineonline.com

Four-Biomarker Blood Test Could Improve Early Pancreatic Cancer Detection

000

Precision Oncology News @preconcnews.bsky.social · 31/01/2026

precisionmedicineonline.com

Four-Biomarker Blood Test Could Improve Early Pancreatic Cancer Detection

010

Precision Oncology News @preconcnews.bsky.social · 31/01/2026

Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of HER2 treatment Phesgo.

precisionmedicineonline.com

Roche Anticipating Giredestrant Approval in 2026, Touts 'Discipline' and 'Stability'

000

Precision Oncology News @preconcnews.bsky.social · 30/01/2026

precisionmedicineonline.com

Four-Biomarker Blood Test Could Improve Early Pancreatic Cancer Detection

000

Precision Oncology News @preconcnews.bsky.social · 30/01/2026

The panel, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.

precisionmedicineonline.com

Four-Gene Blood Biomarker Test Could Improve Early Pancreatic Cancer Detection

001

Precision Oncology News @preconcnews.bsky.social · 30/01/2026

Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of HER2 treatment Phesgo.

precisionmedicineonline.com

Roche Anticipating Giredestrant Approval in 2026, Touts 'Discipline' and 'Stability'

000

Precision Oncology News @preconcnews.bsky.social · 29/01/2026

UniQure had planned to seek accelerated approval for AMT-130 early 2026, but then said its plans were stalled after unexpected FDA feedback.

precisionmedicineonline.com

Huntington's Groups Urge FDA to Review UniQure's Gene Therapy

000

Precision Oncology News @preconcnews.bsky.social · 29/01/2026

Medicare lab spending totaled $8.4 billion in 2024, up 5 percent year over year, with $3.6 billion of that spent on genetic testing, an increase of 20 percent over 2023.

precisionmedicineonline.com

Genetic Testing Driving Increase in Medicare Lab Spending, According to HHS OIG Report

000

Precision Oncology News @preconcnews.bsky.social · 29/01/2026

After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a major shortcoming of the test provided to the family.

precisionmedicineonline.com

Genetic Testing Challenges in Precision Medicine: Inadequate Relay of Test Limits Delays Diagnosis

000

Precision Oncology News @preconcnews.bsky.social · 28/01/2026

While labs overwhelmingly welcomed the ruling, it could make it more difficult for firms that want FDA's imprimatur for LDTs to get such tests reviewed by the agency.

precisionmedicineonline.com

Legal Ruling on FDA Authority Over LDTs Raises Questions for Advanced Dx, CDx Developers

000

Precision Oncology News @preconcnews.bsky.social · 28/01/2026

After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a major shortcoming of the test provided to the family.

precisionmedicineonline.com

Genetic Testing Challenges in Precision Medicine: Inadequate Relay of Test Limits Delays Diagnosis

011

Precision Oncology News @preconcnews.bsky.social · 27/01/2026

The company, founded by UC Berkeley scientists including Jennifer Doudna, is preparing to test its lead candidate STX-1150 in hypercholesterolemia.

precisionmedicineonline.com

CRISPR Biotech Scribe Therapeutics Advancing First Medicine Into Clinic This Year

000

Precision Oncology News @preconcnews.bsky.social · 27/01/2026

While labs overwhelmingly welcomed the ruling, it could make it more difficult for firms that want FDA's imprimatur for LDTs to get such tests reviewed by the agency.

precisionmedicineonline.com

Legal Ruling on FDA Authority Over LDTs Raises Questions for Advanced Dx, CDx Developers

000

Precision Oncology News @preconcnews.bsky.social · 24/01/2026

At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to cancer and rare disease mRNA programs.

precisionmedicineonline.com

Moderna Assures Vaccine De-prioritization in US Doesn't Apply to Cancer

010

Precision Oncology News @preconcnews.bsky.social · 23/01/2026

Amid growing evidence suggesting circadian rhythms play a critical in the safety and efficacy of CAR T-cell therapy, researchers are calling for prospective validation.

precisionmedicineonline.com

Can the Time of Day Patients Receive CAR-T Therapy Influence How Well They Do?

002

Precision Oncology News @preconcnews.bsky.social · 22/01/2026

Researchers explored why only 40 percent of patients responded to Amgen's Imdelltra using TellBio's liquid biopsy test and showed its potential as a non-invasive companion diagnostic.

precisionmedicineonline.com

Circulating Tumor Cell Assay Finds Best Responders to Amgen's Small Cell Lung Cancer Drug

000

Precision Oncology News @preconcnews.bsky.social · 22/01/2026

Mira is bringing its version of Oxford Cancer Biomarkers' PGx test to the US in the newly launched ToxNav Advantage assay.

precisionmedicineonline.com

Mira Precision Health Enters US DPYD Testing Market With Expanded Assay for Chemo Risks

000

Precision Oncology News @preconcnews.bsky.social · 22/01/2026

If the provision passes as part of the bill, it would address a major priority of many firms in the MCED business.

precisionmedicineonline.com

Pathway to Medicare Coverage for MCED Tests Included in Federal Spending Package

000

Precision Oncology News @preconcnews.bsky.social · 21/01/2026

The company discussed plans to leverage MRD in drug development during a call to discuss Q4 and full-year 2025 financials.

precisionmedicineonline.com

J&J Expects Multiple Myeloma Programs to Benefit From FDA MRD Guidance

000

Precision Oncology News @preconcnews.bsky.social · 20/01/2026

All patients with autoimmune hemolytic anemia in a small study initially achieved remission, though two eventually relapsed, opening the way for more research.

precisionmedicineonline.com

CAR-T Therapy Shows Promise in Another Autoimmune Condition

000

Precision Oncology News @preconcnews.bsky.social · 18/01/2026

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in stiff person syndrome.

precisionmedicineonline.com

Kyverna Prepping for First Potential CAR T-Cell Therapy for Autoimmune Disease

012

Precision Oncology News @preconcnews.bsky.social · 17/01/2026

The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this year.

precisionmedicineonline.com

Opus Genetics Advancing LCA5 Vision Loss Gene Therapy Into Pivotal Testing

010

Precision Oncology News @preconcnews.bsky.social · 17/01/2026

The trials will test the ability of the firm's fluorine-18 labeled PET tracer to detect FAP-expressing tumor cells in patients with gastroesophageal and pancreatic cancers.

precisionmedicineonline.com

Sofie Launches Two Phase III Radiopharmaceutical Diagnostic Studies

010

Precision Oncology News @preconcnews.bsky.social · 16/01/2026

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in stiff person syndrome.

precisionmedicineonline.com

Kyverna Prepping for First Potential CAR T-Cell Therapy for Autoimmune Disease

000

Precision Oncology News @preconcnews.bsky.social · 16/01/2026

The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this year.

precisionmedicineonline.com

Opus Genetics Advancing LCA5 Vision Loss Gene Therapy Into Pivotal Testing

000

Precision Oncology News @preconcnews.bsky.social · 16/01/2026

The firm said at the JP Morgan Healthcare Conference that it wants zorevunersen to be approved as a disease-modifying treatment and not just a seizure reducer.

precisionmedicineonline.com

Stoke Eyes 2027 New Drug Application for Dravet ASO After Fast Phase III Enrollment

000

Precision Oncology News @preconcnews.bsky.social · 15/01/2026

The trials will test the ability of the firm's fluorine-18 labeled PET tracer to detect FAP-expressing tumor cells in patients with gastroesophageal and pancreatic cancers.

precisionmedicineonline.com

Sofie Launches Two Phase III Radiopharmaceutical Diagnostic Studies

000